Evidence map›Paper›PMID 29094308›Full record

ArticleInflammopharmacology2018

Ameliorative potential of rutin in combination with nimesulide in STZ model of diabetic neuropathy: targeting Nrf2/HO-1/NF-kB and COX signalling pathway.

Ruchika Mittal, Anil Kumar, Dhirendra Pratap Singh, Mahendra Bishnoi, Tapas Chandra Nag

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammopharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 66 citations in OpenAlex.

  1. Light-driven bacterial inactivation using Plumeria rubra extract: a promising natural photosensitizer.International microbiology : the official journal of the Spanish Society for Microbiology · 2026
    Article
  2. Article
  3. Article
  4. Chemical Profile and In Vitro Protective Effects ofPlants (Basel, Switzerland) · 2025
    Article
  5. Article
  6. Review
  7. Rutin: a pain-relieving flavonoid.Inflammopharmacology · 2025
    Review
  8. Article
  9. Antiapoptotic and antinociceptive effects ofResearch in pharmaceutical sciences · 2024
    Article
  10. Diabetic neuropathy: A NRF2 disease?Journal of diabetes · 2024
    Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Ruchika MittalNeuropharmacology Division, University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Study, Panjab University, Chandigarh, 160014, India.
Anil KumarNeuropharmacology Division, University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Study, Panjab University, Chandigarh, 160014, India. kumaruips@yahoo.com.
Dhirendra Pratap SinghNational Agri-Food Biotechnology Institute (NABI), Sector-81, SAS Nagar, Mohali, 140306, Punjab, India.
Mahendra BishnoiNational Agri-Food Biotechnology Institute (NABI), Sector-81, SAS Nagar, Mohali, 140306, Punjab, India.
Tapas Chandra NagDepartment of Anatomy, All India Institute of Medical Sciences, New Delhi, India.
National Agri-Food Biotechnology Institute · INPanjab University · INAll India Institute of Medical Sciences · IN

Funding

Department of Science and Technology, New Delhi Grant SR/WOS-A/LS-1324/2014 dated 14.05.2015
6 · The paper itself

Abstract

Emerging role of Nrf-2/HO-1 in pathogenesis of diabetic neuropathy has been suggested. Diabetic neuropathy is one of the most common complications of diabetes and more than 50% patients of diabetes develop diabetic neuropathy. Rutin has been well documented to show protective effect in various complications, e.g., diabetic neuropathy. However, its mechanistic insight is still not completely understood. The present study has been designed to explore the protective effect of rutin and its interaction with COX-2 inhibitor, nimesulide in diabetic neuropathy. DN (diabetic neuropathy) rats were maintained with or without rutin (100 and 200 mg/kg), nimesulide (5 and 10 mg/kg), and their combinations for 8 weeks. Body weight, serum glucose, pain assessment (mechanical allodynia, cold allodynia, mechanical hyperalgesia, and thermal hyperalgesia), and motor nerve conduction velocity (MNCV) were measured in all groups. Oxidative damage was assessed through biochemical estimation and mitochondrial ROS production, followed by inflammatory and apoptotic markers (TNF-α, caspase-3, Nrf-2, HO-1, and NF-kBp65) for their activity, protein, and gene expression. The structural changes were also reported through transmission electron microscope. Streptozotocin injection (55 mg/kg) induced diabetes reduced body weight, reduced the threshold for pain in various pain assessment parameters. Oxidative damage (increased MDA, decreased SOD, catalase, and GSH levels) increased mitochondrial ROS production followed by increased expression of inflammatory markers and decreased expression of Nrf-2/HO-1 in sciatic nerve. Treatment with rutin (100 and 200 mg/kg) and nimesulide (5 and 10 mg/kg) significantly attenuates these alterations as compared to DN control rats. Furthermore, combination of rutin (200 mg/kg) and nimesulide (10 mg/kg) significantly potentiated their protective effect which was significant as compared to their effect alone in streptozotocin-treated rats. The present study suggests the involvement of Nrf-2/HO-1 pathway in the protective effect of rutin against streptozotocin-induced diabetic neuropathy.

Indexed as

AnimalsCyclooxygenase 2Cyclooxygenase InhibitorsDiabetes Mellitus, ExperimentalDiabetic NeuropathiesDrug Delivery SystemsDrug Therapy, CombinationHeme Oxygenase-1MaleMembrane ProteinsNF-E2-Related Factor 2NF-kappa BRatsRutinSignal TransductionStreptozocinCyclooxygenase 2Cyclooxygenase InhibitorsHeme Oxygenase-1Hmox1 protein, mouseMembrane ProteinsNF-E2-Related Factor 2NF-kappa BnimesulidePtgs2 protein, ratRutinStreptozocinSulfonamidesDiabetic neuropathyHO-1InflammationNimesulideNrf-2Rutin

Identifiers

PMID29094308
OpenAlexW2765841182

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.